Navigation Links
Delcath Systems Announces the Sale of 5,185,000 Shares of Common Stock
Date:8/16/2010

NEW YORK, Aug. 16 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company"), today announced the sale of 5,185,000 shares of its common stock pursuant to an underwriting agreement with Canaccord Genuity acting as the sole bookrunner.  The last reported sale price of the Company's common stock as reported by the Nasdaq Capital Market on August 16, 2010 was $7.15 per share.

The Company expects to use the net proceeds from the sale of the shares for funding of its clinical trials, research and development, obtaining regulatory approvals, manufacturing, operations, sales, commercialization of its products and other general corporate purposes, including capital expenditures and working capital.  Closing of the offering is expected to occur on or about August 20, 2010, subject to customary closing conditions.  In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 777,750 shares of common stock to cover over-allotments, if any.

The offering is being made pursuant to an effective shelf registration statement.  Before you invest, you should read the base prospectus in such shelf registration statement, the prospectus supplement, when available, and other documents the Company has filed with the Securities and Exchange Commission for more complete information about the Company and this offering.  The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending a request to the offices of Canaccord Genuity, Attn: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, phone: (800) 225-6201.  Alternatively, you may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Delcath Systems

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology.  Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents.  The Company's initial focus is on the treatment of primary and metastatic liver cancers.  Delcath recently concluded a Phase III metastatic melanoma study, and the Company is currently conducting a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system.  For more information, please visit the Company's website at www.delcath.com.  

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug-delivery system for the treatment of other liver cancers and other organs, the potential of chemosaturation therapy via PHP as a treatment for patients with terminal metastatic disease in the liver, actions by the FDA or other regulatory agencies, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets,  and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Delcath Highlights Phase III Trial Results Presented at ASCO
2. Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
3. Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
4. Delcath Systems Receives Preliminary Notification of Inclusion in Russell 3000(R) Index
5. Delcath Enters Agreement to Sell 869,565 Units
6. Delcath Systems Granted Third Orphan Drug Designation
7. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
8. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
9. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
10. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
11. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 /PRNewswire/ ... their $7M Series B financing, adding an additional $3M ... led by Mesa Verde Venture Partners and other strategic ... be directed towards further accelerating commercial adoption of their ... profiling test and expanding the Paradigm cancer registry. ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search firm, ... Officer with GenePeeks. Matt is a veteran life sciences and molecular diagnostics ... company focused on identifying inherited disease risk in future generations. In his new ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. („TRIANNI") ... Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung der ... führenden Plattform für die Entdeckung monoklonaler Antikörper. ... neuartiges chimäres Gensegmentdesign aus, das Janssen den ... Antikörpern bietet und das für die schelle Isolierung ...
Breaking Biology Technology:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent ... availability of a new report, Sensors for Robotics: Technologies, Markets ... ... ... IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine ...
(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading ... a new solution aimed at combatting fraud, waste and ... was introduced at the Action on Disaster Relief conference ... meeting point for UN agencies and foreign assistance organizations ... Fraud, waste and abuse are a largely unacknowledged problem ...
Breaking Biology News(10 mins):